Barinthus Biotherapeutics plc. — fact timeline

Barinthus Biotherapeutics plc. shareholders approved Approve the Scheme Implementation Proposal at the 2026-05-20 meeting.

“1. To approve the Scheme Implementation Proposal. 24,710,187 3,922 10 0”

Barinthus Biotherapeutics plc. shareholders approved Approve the Scheme of Arrangement at the 2026-05-20 meeting.

“1. To approve the Scheme Proposal. 24,709,337 3,772 0 0”

Barinthus Biotherapeutics plc. reported quarter ended March 31, 2026 results: net income net loss attributable to its shareholders of $5.5 million, or $(0.14) per share, EPS $(0.14) per share.

“For the first quarter of 2026, the Company generated a net loss attributable to its shareholders of $5.5 million, or $(0.14) per share on both basic and fully diluted bases”

Barinthus Biotherapeutics plc. reported financial results for the year ended December 31, 2025.

“On March 13, 2026, Barinthus Biotherapeutics plc (the “Company”) provided an overview of the Company’s progress and announced its financial results for the year ended December 31, 2025.”

Barinthus Biotherapeutics plc. amended Amendment to the Agreement and Plan of Merger with Clywedog Therapeutics, Inc. valued at Amendment to exchange ratios and minimum cash requirements in connection with scheme of arrangement (effective 2026-02-22).

“On February 22, 2026, the Beacon, Topco, Merger Sub and Clywedog entered into the Amendment to the Agreement and Plan of Merger”

Barinthus Biotherapeutics plc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).

“December 30, 2025, Barinthus Biotherapeutics plc (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) indicating that the closing bid price of the Company’s American Depositary Shares (the “ADS”), each representing one ordinary share of the Company, was below $1.00 per share for 30 consecutive business days, and that, therefore, the Company is not in compliance with Nasdaq Listing Rule 5450(a)(1), which is the minimum bid price requirement for continued listing on the Nasdaq Global Market. The notice from Nasdaq has no immediate effect on the listing of the ADSs, and t”

Gemma Brown was appointed as principal accounting officer at Barinthus Biotherapeutics plc..

“and Ms. Brown as principal accounting officer”

William Enright was appointed as principal financial officer at Barinthus Biotherapeutics plc..

“appointed William Enright, the Company’s Chief Executive Officer, as principal financial officer”

Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

“Effective as of April 30, 2025, the Company terminated the employment of Gemma Brown as Chief Financial Officer in connection with its restructuring plan that was announced in 2025.”

Barinthus Biotherapeutics plc. announced a restructuring with charges of in the region of $2.5 million affecting UK (65% reduction in workforce).

“On January 10, 2025, the Company announced a restructuring plan that aims to prioritize its immune tolerance research and development programs. The Company is planning a 65% reduction in workforce, which is subject to consultation with employee representatives in the UK regarding the plan. The Company anticipates that the majority of the reduction in workforce will occur in the UK and be completed during the first half of 2025. The Company estimates that the pre-tax costs of such reduction in workforce relating to employee severance and other employee-related costs may be in the region of $2.5 million with the majority of such costs being incurred in the first half of 2025.”

Gemma Brown was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

“the employment of Gemma Brown effective as of April 30, 2025”

Graham Griffiths was terminated as Chief Operating Officer at Barinthus Biotherapeutics plc..

“the Company will terminate the employment of Graham Griffiths effective as of June 30, 2025”

Nadège Pelletier departed as Chief Scientific Officer at Barinthus Biotherapeutics plc..

“On November 25, 2024, Nadège Pelletier, Ph.D., notified Barinthus Biotherapeutics plc (the "Company") that she will step down as Chief Scientific Officer of the Company effective February 2, 2025.”

Graham Griffiths changed role as Chief Operating Officer at Barinthus Biotherapeutics plc..

“Effective September 1, 2024 (the “Effective Date”), Barinthus Biotherapeutics plc (the “Company”) has promoted Graham Griffiths, the Company’s Chief Business Officer, to Chief Operating Officer.”

Barinthus Biotherapeutics plc. shareholders approved Receive and approve on advisory basis the Company’s U.K. statutory directors’ compensation report for fiscal year ended December 31, 2023 at the 2024-05-10 meeting.

“To receive and approve on an advisory basis the Company’s U.K. statutory directors’ compensation report for the fiscal year ended December 31, 2023 19,030,522 4,633 16,819 3,000,133”

Barinthus Biotherapeutics plc. shareholders approved Receive the U.K. statutory annual accounts and reports for fiscal year ended December 31, 2023 and note no dividend at the 2024-05-10 meeting.

“To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2023 and to note that the Company’s directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2023 19,034,966 304 16,704 3,000,133”

Barinthus Biotherapeutics plc. shareholders approved Authorize the Audit Committee to determine the Company’s auditors’ remuneration for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.

“To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2024 19,035,192 171 16,611 3,000,133”

Barinthus Biotherapeutics plc. shareholders approved Ratify the appointment of PricewaterhouseCoopers LLP as independent registered public accounting firm for fiscal year ending December 31, 2024 at the 2024-05-10 meeting.

“To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 22,035,421 34 16,651 1”

Barinthus Biotherapeutics plc. shareholders approved Re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company at the 2024-05-10 meeting.

“To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 22,035,376 81 16,650 0”

Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Robin Wright, who retires by rotation at the 2024-05-10 meeting.

“To re-elect as a director, Robin Wright, who retires by rotation in accordance with the Company’s Articles of Association 18,885,204 166,609 161 3,000,133”

Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, Alex Hammacher, who retires by rotation at the 2024-05-10 meeting.

“To re-elect as a director, Alex Hammacher, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133”

Barinthus Biotherapeutics plc. shareholders approved Re-elect as a director, William Enright, who retires by rotation at the 2024-05-10 meeting.

“To re-elect as a director, William Enright, who retires by rotation in accordance with the Company’s Articles of Association 18,871,704 180,109 161 3,000,133”

Barinthus Biotherapeutics plc. reported first quarter of 2024 results: revenue nil.

“On May 13, 2024, the Company announced its financial results for the first quarter of 2024”

Barinthus Biotherapeutics plc. reported financial results for first quarter of 2024.

“On May 13, 2024, Barinthus Biotherapeutics plc (the “Company”) announced its financial results for the first quarter of 2024 and provided an overview of the Company’s progress. The full text of the press release issued in connection with the update is furnished as Exhibit 99.1 to this Current Report on Form 8-K.”

Barinthus Biotherapeutics plc. reported the year ended December 31, 2023 results: revenue $0.8 million, net income net loss of $73.4 million.

“• Cash position: As of December 31, 2023, cash was $142.1 million, compared to $194.4 million as of December 31, 2022. The cash used in operating activities was $50.9 million, primarily resulting from our net loss of $73.4 million, adjusted by foreign exchange loss on translation of $7.5 million, share-based compensation of $5.1 million, depreciation and amortization of $5.4 million, deferred tax movements of $3.1 million and changes in our operating assets and liabilities, net of $6.2 million primarily related to a $5.8 million decrease in accounts receivable, a $2.2 million decrease in prepaid expenses and other current assets, $3.4 million decrease in accounts payable and $2.0 million increase in accrued expenses. • Revenue: Revenue was $0.8 million in 2023 compared to $44.7 million in 2022 and was comprised of the Company’s share of royalties received by Oxford University Innovation as a result of commercial sales of Vaxzevria® by AstraZeneca, sales of which reduced significantly i”

Barinthus Biotherapeutics plc. entered into Funding Agreement with Coalition for Epidemic Preparedness Innovations (CEPI) and the Chancellors, Masters and Scholars of the University of Oxford valued at up to $34.8 million (effective 2023-12-20).

“On December 20, 2023, Barinthus Biotherapeutics plc (the “Company”), the Chancellors, Masters and Scholars of the University of Oxford (“Oxford,” together with the Company, the “Partners”) and the Coalition for Epidemic Preparedness Innovations (“CEPI”) entered into a Funding Agreement (the “Funding Agreement”) pursuant to which CEPI will provide funding of up to $34.8 million to the Company to advance the development of VTP-500, the Company’s vaccine candidate against Middle East Respiratory Syndrome (“MERS,” and such development activities, the “Project”).”

Barinthus Biotherapeutics plc. reported third quarter of 2023 results: net income $14.1 million, EPS $0.37 per share on both basic and fully diluted bases.

“For the third quarter of 2023, the Company generated a net loss attributable to its shareholders of $14.1 million, or $0.37 per share on both basic and fully diluted bases, compared to a net loss attributable to shareholders of $23.8 million, or $0.62 per share on both basic and fully diluted bases in the second quarter of 2023.”

Barinthus Biotherapeutics plc. shareholders approved Disapplication of pre-emption rights (Special Resolution) at the 2023-11-06 meeting.

“For Against Withheld Broker Non-Votes THAT, conditional upon Resolution 1 above being duly passed, the directors of the Company or any duly authorized committee of the directors be generally empowered pursuant to section 570 of the U.K. Companies Act 2006 to allot equity securities (within the meaning of the U.K. Companies Act 2006) for cash pursuant to the authority conferred on them by Resolution 1 as if section 561 of the U.K. Companies Act 2006 and any pre-emption provisions in the articles of association of the Company (or howsoever otherwise arising) did not apply to the allotment for a period expiring (unless previously renewed, varied or revoked by the Company prior to or on that date) five years after the date on which this Resolution is passed save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted after such expiry and the directors may allot shares in pursuance of any such offer or agreement notwithstandin”

Barinthus Biotherapeutics plc. shareholders approved Authorization to allot shares (Ordinary Resolution) at the 2023-11-06 meeting.

“For Against Withheld Broker Non-Votes THAT, in accordance with section 551 of the U.K. Companies Act 2006, the directors of the Company or any duly authorized committee of the directors be generally and unconditionally authorized to allot shares in the Company or grant rights to subscribe for or to convert any security into shares in the Company (“Rights”) up to an aggregate nominal amount of £1,928 for a period expiring (unless previously renewed, varied or revoked by the Company in general meeting) five years after the date on which this Resolution is passed, save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or Rights to be granted and the directors may allot shares or grant Rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this Resolution has expired. The authority referred to in this Resolution is in addition to all subsisting authorities conferred on the director”

Barinthus Biotherapeutics plc. reported second quarter of 2023 results: revenue $0.3 million.

“plans, we expect our cash runway to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. 2 · Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023. Revenue was comprised of the Company’s share of royalties received by Oxford University”

Dr. Margaret Marshall retired as Chief Medical Officer at Barinthus Biotherapeutics plc..

“On July 20, 2023, Dr. Margaret Marshall notified Vaccitech plc (the “Company”) of her intention to retire from her position as Chief Medical Officer of the Company, effective immediately.”

Barinthus Biotherapeutics plc. reported financial results for the first quarter of 2023.

“today announced its financial results for the first quarter of 2023”

Barinthus Biotherapeutics plc. shareholders approved To receive and approve on an advisory basis the Company’s U.K. statutory directors’ compensation report for the fiscal year ended December 31, 2022, which is set forth in Annex A to the Company’s proxy statement at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to note that the Company’s directors do not recommend the payment of any dividend for the fiscal year ended December 31, 2022 at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Barinthus Biotherapeutics plc. shareholders approved To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association at the 2023-05-11 meeting.

“Ordinary Resolutions For Against Withheld Broker Non- Votes To re-elect as a director, Karen T. Dawes, who retires by rotation in accordance with the Company’s Articles of Association 18,831,028 843,290 65 0 To re-elect as a director, Anne M. Phillips, who retires by rotation in accordance with the Company’s Articles of Association 19,653,086 21,232 65 0 To re-appoint PricewaterhouseCoopers LLP as U.K. statutory auditors of the Company, to hold office until the conclusion of the next annual general meeting of shareholders 19,653,422 20,896 65 0 To ratify the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 19,653,687 20,696 0 0 To authorize the Audit Committee to determine the Company’s auditors’ remuneration for the fiscal year ending December 31, 2023 19,653,366 20,696 321 0 To receive the U.K. statutory annual accounts and reports for the fiscal year ended December 31, 2022 and to no”

Chris Ellis retired as Chief Operating Officer at Barinthus Biotherapeutics plc..

“On April 24, 2023, Chris Ellis, our Chief Operating Officer (principal operating officer), informed Vaccitech plc (the “Company”) of his retirement from the Company, effective October 31, 2023.”

Barinthus Biotherapeutics plc. reported the full year ended December 31, 2022 results: revenue $43.7 million.

“The Company’s share of milestone and royalty payments received by Oxford University Innovation (OUI) from AstraZeneca which were recognized as revenue for the year ended December 31, 2022 amounted to $43.7 million.”

Barinthus Biotherapeutics plc. reported third quarter ended September 30, 2022 results: revenue $6.2 million, net income $8.2 million, EPS $0.22 both per fully diluted share and per basic share.

“Revenues comprised primarily of the Company’s share of milestone and royalty payments received by OUI from AstraZeneca related to commercial sales of Vaxzevria ® . Revenues were $6.2 million in the third quarter of 2022 compared to $17.1 million in the second quarter of 2022, with the reduction attributable to no milestones being achieved in the third quarter of”

Gemma Brown was appointed as Chief Financial Officer at Barinthus Biotherapeutics plc..

“the Board of Directors (the “Board”) of the Company had appointed Gemma Brown as the Company’s Chief Financial Officer.”

Georgy Egorov was terminated as Chief Financial Officer at Barinthus Biotherapeutics plc..

“On September 14, 2022, the Company terminated the employment of Georgy Egorov in its entirety, effective immediately.”

Gemma Brown was appointed as Chief Financial Officer at Barinthus Biotherapeutics plc..

“Effective September 15, 2022, the Board of Directors (the “Board”) of Vaccitech plc (the “Company”) appointed Gemma Brown, age 32, as the Company’s Chief Financial Officer.”